Dianthus Therapeutics
Waltham, US · Founded 2019 · Delaware corporation · 127 employees on LinkedIn · 1 known investors
Dianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection. The company operates in the biotech and drug development sector.
Founders & leadership
Dianthus Therapeutics was founded in 2019 by Jonathan Violin.
JV
Jonathan ViolinFounder
KE
Kenneth Evan ThompsonExecutive
Board
LM
Leon MoulderBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$121.5M disclosed across 4 rounds · 2019–2022
▶$100MraisedApr 2022 · 22 investors · BiotechnologyRule 506(b)
▶$100MraisedApr 2022 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tomas KiselakDirector
- Kenneth Evan ThompsonExecutive Officer
- Paula SoteropoulosDirector
- Jonathan ViolinDirector
- Leon O. Moulder, Jr.Director
- Lei MengDirector
- Marino GarciaExecutive Officer, Director
- Offering amount
- $100M
- Amount sold
- $100M
- Sales commissions
- $3M
- Placement agents
- Jefferies LLC
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$15MraisedJun 2021 · 6 investors · BiotechnologyRule 506(b)
▶$15MraisedJun 2021 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tomas KiselakDirector
- Leon O. Moulder, Jr.Director
- Kenneth Evan ThompsonExecutive Officer
- Jonathan ViolinExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$7.7KraisedApr 2021 · 1 investors · BiotechnologyRule 506(b)
▶$7.7KraisedApr 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth Evan ThompsonExecutive Officer
- Jonathan ViolinExecutive Officer, Director
- Leon MoulderDirector
- Offering amount
- $7.7K
- Amount sold
- $7.7K
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$6.5MraisedDec 2020 · 6 investors · BiotechnologyRule 506(b)
▶$6.5MraisedDec 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Leon Moulder, Jr.Director
- Jonathan ViolinExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $6.5M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Dianthus Therapeutics do?
- Dianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection. The company operates in the biotech and drug development sector.
- Who founded Dianthus Therapeutics?
- Dianthus Therapeutics was founded by Jonathan Violin in 2019.
- Who are Dianthus Therapeutics's investors?
- Dianthus Therapeutics's investors include 5AM Ventures.
- How much funding has Dianthus Therapeutics raised?
- Dianthus Therapeutics has disclosed $121.5M raised across 4 rounds.
- Where is Dianthus Therapeutics headquartered?
- Dianthus Therapeutics is headquartered in Waltham, US.